AstraZeneca shares plunge 8.9% after reports of BMS talks

Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors remain sceptical about the strategic rationale and regulatory feasibility of such a deal.

AstraZeneca (AZ) shares tumbled by as much as 8.9% on Monday, wiping more than GBP£17 billion off the value of Britain's largest drugmaker, after reports emerged that the company had held preliminary discussions with Bristol Myers Squibb (BMS) about a potential mega-merger that would create one of the world's largest pharmaceutical companies with a combined value approaching $400 billion. The sharp decline pushed AZ's market capitalisation down to approximately GBP£178 billion, causing it to lose its position as the UK's second-largest listed company to Shell.

The Financial Times first reported on Sunday that the two pharmaceutical giants had engaged in talks about a possible combination, though sources indicated that there is no certainty a deal will materialise. Neither company has confirmed the discussions, with AZ declining to comment and BMS not responding to requests for comment. Reuters subsequently confirmed the talks with a person familiar with the situation, though it remains unclear whether discussions are ongoing.

The market reaction reflected widespread investor scepticism about the strategic rationale for such a transaction, particularly from AZ's perspective. The Cambridge-based company has been one of the pharmaceutical industry's strongest growth stories under the leadership of CEO Pascal Soriot, who has overseen a more than fourfold increase in the share price during his 14-year tenure. The company is targeting US$80 billion in sales by 2030, up from US$58.7 billion last year, driven by strong demand for its cancer and rare disease treatments. Oncology drugs alone accounted for approximately US$25 billion in sales in 2025, representing nearly half of total revenues.

Analysts expressed surprise and confusion at the prospect of AZ pursuing such a deal given its best-in-class pipeline and robust growth trajectory. BMO Capital Markets noted that significant business overlap between the two companies would likely reduce the odds of a successful merger, pointing to several areas where their commercial portfolios compete directly. Both companies have substantial oncology franchises, with cancer immunotherapies that compete head-to-head in the market. Oncology drugs accounted for more than 40% of BMS' overall sales in the first half of 2026, creating potential antitrust concerns.

The regulatory hurdles facing any potential transaction would be formidable. Antitrust officials on both sides of the Atlantic would be expected to scrutinise the deal intensively, given the overlapping product portfolios and late-stage pipeline assets. Andre Barlow, an antitrust lawyer with DBM Law Group, suggested that even under a Trump administration Federal Trade Commission, the merger would face significant scrutiny and would likely require meaningful divestitures if there are substantial overlaps in certain drugs and late-stage pipeline candidates.

Despite the regulatory challenges, there are potential strategic rationales for a combination. The clearest logic centres on US market exposure. AZ's US sales accounted for 42% of total revenues in the first half of 2026, whilst BMS sourced 69% of revenues from the US in the most recent quarter. A merger would substantially deepen AZ's American commercial presence and would follow the company's completion of a direct listing on the New York Stock Exchange in June. AZ is already investing $50 billion in US research and manufacturing through 2030, and acquiring BMS would dramatically accelerate its American expansion.

Another potential rationale relates to the increasing importance of combination therapies in oncology. The ability to develop and commercialise more complex multi-drug regimens without cross-company negotiations could prove one of the most compelling strategic arguments for a merger, particularly as combination therapies increasingly define the standard of care in cancer treatment.

For BMS, the strategic imperative may be more pressing. The company has been pursuing smaller acquisitions to gain new drugs as it faces declining sales of older medicines, some of which will soon face generic competition. In 2019, BMS acquired Celgene for approximately US$80 billion, gaining its flagship blood cancer drug Revlimid, which became BMS' top-selling product. However, Revlimid has already lost patent protection, and the company's current top sellers—cancer immunotherapy Opdivo and blood thinner Eliquis—could lose patent protection by 2028, creating significant revenue pressures.

Market reactions diverged sharply between the two companies. Whilst AZ's shares plunged in London trading, BMS' shares initially rose by as much as 6% in US pre-market trading before reversing course and losing those gains by midday in New York. The contrasting movements reflect investor perceptions that BMS shareholders might benefit from a premium acquisition price, whilst AZ shareholders question whether the company needs to pursue such a transformative and risky transaction given its strong standalone prospects.

If completed, the deal would rank among the largest pharmaceutical mergers in history and would create the world's fourth-largest drugmaker by market value. However, the combination of significant antitrust concerns, substantial portfolio overlaps, and questions about strategic fit suggest that any potential transaction faces considerable obstacles. The talks also raise concerns about a potential shift of AZ's focus away from the UK, despite its status as one of Britain's most valuable companies and a flagship of the country's life sciences sector.

Source: AstraZeneca investors balk at $400 billion Bristol Myers tie-up reports [Accessed August 4, 2026] https://www.reuters.com./business/healthcare-pharmaceuticals/astrazeneca-shares-tumble-7-after-reported-bristol-myers-talks-2026-08-03/